NCT07007559Phase 2Recruiting

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Study sponsor: ALX Oncology Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12Estimated
Enrollment · participants120Estimated
Source updated2026-11-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: MBC substudy: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment. After: Measure: Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessment.

Planned enrollment increased by 40 participants

Before: 80 participants (planned). After: 120 participants (planned).

Primary completion date changed

Before: Jun 2027. After: Dec 2027.

Phase changed

Before: PHASE1, PHASE2. After: PHASE2.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview